Table 1.
Mirabegron | Tamsulosin | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
#1 | #3 | #4 | #5 | #7 | #9 | #10 | #2 | #6 | #8 | #1 | #2 | |
Phe-86 | + | + | + | + | ||||||||
Trp-102 | + | + | ||||||||||
Ala-103 | + | + | + | + | + | + | + | + | + | |||
Asp-106 | + | + | + | + | ||||||||
Val-107 | + | + | + | + | + | + | + | + | + | |||
Cys-110 | + | |||||||||||
Ser-158 | + | + | + | + | + | + | + | |||||
Pro-161 | + | + | + | + | + | |||||||
Leu-162 | + | + | + | + | + | + | + | |||||
Gln-177 | + | + | ||||||||||
Ile-178 | + | + | + | + | + | + | + | + | + | + | + | |
Asn-179 | + | + | + | + | + | + | + | |||||
Glu-180 | + | + | ||||||||||
Val-185 | + | + | + | + | + | + | + | |||||
Ser-188 | + | + | + | + | + | |||||||
Phe-288 | + | + | + | + | + | + | + | |||||
Phe-289 | + | + | + | + | + | + | + | |||||
Met-292 | + | + | + | + | + | + | + | |||||
Gly-295 | + | |||||||||||
Pro-303 | + | + | + | |||||||||
Glu-305 | + | |||||||||||
Phe-308 | + | + | + | |||||||||
Lys-309 | + | + | + | + | + | |||||||
Phe-312 | + | + | ||||||||||
Number of close contacts | 13 | 12 | 11 | 13 | 12 | 10 | 11 | 7 | 6 | 5 | 8 | 10 |
Shared contacts | ala-103, val-107, ser-158, leu-162, ile-178, asn-179, val-185, phe-288, phe-289, met-292 | phe-86, pro-303, phe-308, lys-309 | trp-102, ala-103, asp-106, val-107, gln-177, ile-178, lys-309, phe-312 | |||||||||
Orientation of bound ligand | Slope, slightly vertical | Horizontal, only receptor surface | vertical |